IXICO plc New contract to support Phase II clinical trial (6071S)

TIDMIXI

RNS Number : 6071S

IXICO plc

04 October 2017

4 October 2017

IXICO plc

("IXICO" or the "Company")

IXICO signs new contract to deploy biosensors in a Phase II neurological clinical trial

First commercial contract using IXICO's wearable biosensor technology

IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announces that it has signed a new contract, with a top 15 global pharmaceutical company, utilising wrist worn activity sensors ('wearable biosensors') in a Phase II clinical trial for a neurological disorder.

This is IXICO's first commercial agreement using activity sensors to evaluate exploratory digital measures in early phase clinical research and follows a presentation of IXICO's approach to measuring sleep disturbances at the "Mobile devices for clinical trials in neurological diseases workshop" earlier this year at the Clinical Data Interchange Standards Consortium (CDISC) and the Critical Path Institute Coalition Against Major Diseases (CAMD) meetings.

This contract has a value of around GBP0.5m over a two year term, commencing in September 2017. IXICO will utilise its biosensor clinical trial capabilities, combined with its artificial intelligence data analytics algorithms, to measure activity and sleep disturbances from biosensor data collected from c.300 people.

Sleep disturbance is a challenging symptom of many brain diseases including Parkinson's and Alzheimer's Disease and is also a side effect of many drug treatments. The work performed in this clinical trial, represents an important step in the validation of biosensors as new digital technologies in a specific context of use, as required by regulatory authorities.

Giulio Cerroni, CEO of IXICO, commented: "We are delighted to be deploying wearable biosensors and our proprietary algorithms to measure sleep disturbance in a commercial clinical trial. This is an excellent opportunity for IXICO to demonstrate how our biosensor services and technology, build upon our well-established expertise in providing regulatory compliant imaging endpoints in clinical trials, to support the process of developing new drugs to treat neurological diseases."

For further information please contact:

 
 IXICO plc                                 Tel: [phone] 
  Giulio Cerroni, Chief Executive           7499 
  Officer 
  Susan Lowther, Chief Financial Officer 
 
 Shore Capital (Nomad and Broker)          Tel: +44 20 
  Bidhi Bhoma / Edward Mansfield /James     7408 4090 
  Wolfe 
 
 FTI Consulting Limited (Investor          Tel: +44 20 
  Relations)                                3727 1000 
  Simon Conway/Mo Noonan 
 

About IXICO

IXICO is the digital technologies company serving neuroscience. Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.

More information is available on www.IXICO.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

CNTBUBDGXSGBGRX

(END) Dow Jones Newswires

October 04, 2017 02:00 ET (06:00 GMT)